CLDX Celldex Therapeutics, Inc featured news, full reports, and detailed charts
Celldex Therapeutics, Inc (CLDX) Wrap Up:
As used herein, the terms "we," "us," "our," or "AVANT" refer to AVANT Immunotherapeutics, Inc., a Delaware corporation organized in 1983 and its subsidiaries. We are a biopharmaceutical company that uses novel applications of immunology to develop products for the prevention and treatment of diseases. We are developing a broad portfolio of vaccines and immunotherapeutics addressing a wide range of applications including bacterial diseases, food safety and cardiovascular disease. These include single-dose, oral vaccines that protect against important disease-causing infectious agents, a treatment to reduce complement-mediated tissue damage and a novel, proprietary vaccine candidate for cholesterol management. Our strategy is to demonstrate proof-of-concept for our product candidates before leveraging their value through partnerships or, in appropriate situations, continuing late stage development ourselves. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f18%2f0001047469-08-003032.html#FIS_BUSINESS"www.celldextherapeutics.com
78 Employees
Founded in 2003
Celldex Therapeutics, Inc. (CLDX:NASDAQ)
LAST $4.88 USD
CHANGE TODAY -0.03 -0.61%
VOLUME 160.8K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Celldex Therapeutics, Inc. (CLDX)
|
OPEN
$4.88
|
PREVIOUS CLOSE
$4.91
|
|
|
DAY HIGH
$4.89
|
DAY LOW
$4.75
|
|
|
52 WEEK HIGH
06/1/09 - $14.19
|
52 WEEK LOW
10/28/09 - $4.16
|
|
|
MARKET CAP
154.2M
|
AVERAGE VOLUME 3 mo
296.3K
|
|
|
DILUTED EPS TTM
$-1.96
|
SHARES OUTSTANDING
31.6M
|
|
|
CLDX Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Cancer Research Group Releases Data
05/16/2008 12:01 AM ET
To curtail data leaks that can affect drugmakers' stock prices, the American Society of Clinical Oncology discloses trial outcomes before its annual meeting
CLDX Top Compensated Officers
Mr. Anthony S. Marucci
Chief Executive Officer, President and Direct...
Age: 47
Total Annual Compensation: $440.2K
Mr. Avery W. Catlin
Chief Financial Officer, Senior Vice Presiden...
Age: 60
Total Annual Compensation: $319.9K
Dr. Thomas Davis M.D.
Chief Medical Officer and Senior Vice Preside...
Age: 45
Total Annual Compensation: $396.6K
Dr. Tibor Keller Ph.D.
Chief Scientific Officer and Senior Vice Pres...
Age: 50
Total Annual Compensation: $346.6K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc., Annual General Meeting, Dec 16, 2009
11/6/2009
Celldex Therapeutics, Inc., Annual General Meeting, Dec 16, 2009, at 09:00 US Eastern Time. Location: Hilton Boston/Dedham Hotel, 25 Allied Drive, Dedham, MA 02026, United States. Agenda: To elect nine directors to serve until the next Annual Meeting of stockholders and until their respective successors shall have been duly elected and qualified; to ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2009; to approve an amendment to our 2008 Stock Option and Incentive Plan to increase the shares reserved for issuance there under to 3,900,000; to approve an amendment to our 2004 Employee Stock Purchase Plan to increase the shares reserved for issuance there under to 62,500; and to consider any other matters that may properly come before the meeting.
Celldex Therapeutics, Inc. - Conference Presentation Call
11/5/2009
Celldex Therapeutics, Inc. - Conference Presentation Calls
Celldex Therapeutics Inc. Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine-Month Period Ended September 30, 2009
11/4/2009
Celldex Therapeutics Inc. reported unaudited consolidated financial results for the third quarter and nine-month period ended September 30, 2009. The company reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009 compared to a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2008. The net loss is primarily due to an increase in revenue, partially offset by an increase in operating expense and a decrease in investment income. Total revenues were $4.03 million against $2.4 million a year ago. Operating loss was $7.2 million against $8.6 million a year ago. For the nine months ended September 30, 2009, the company reported a net loss of $23.6 million, or $1.49 per share, compared to a net loss of $40.0 million, or $2.92 per share, for the nine months ended September 30, 2008. The net loss is primarily due to the non-cash charge of $14.8 million for purchased in-process R&D recorded in 2008. Total revenues were $10.5 million against $4.5 million a year ago. Revenues for the first nine months of 2009 increased by $6.0 million compared with revenues for 2008. Operating loss was $23.7 million against $41.1 million a year ago.
CLDX Competitors
| Company | Last | Change | |
| No competitor information is available for CLDX. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | CLDX | Industry Range |
| Price/Earnings | -- | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | -- | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
CLDX |
||
|
CLDX transactions
| Type Date |
Target |
|
Merger/Acquisition
May 28, 2009 |
CuraGen Corp. |
More Recent News About Celldex Therapeutics, Inc
More news for CLDX
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition
Show all filings for CELLDEX THERAPEUTICS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for CELLDEX THERAPEUTICS, INC. 2-Oct-2009Entry into a Material Definitive Agreement, Completion of Acquisition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). A...Click here to read the whole Article (external link)
Celldex Therapeutics Announces Completed Acquisition of CuraGen Corporation
NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (Nasdaq: CLDX - News) announced today the successful completion of its acquisition of CuraGen Corporation (Nasdaq: CRGN - News) pursuant to the previously disclosed Agreement and Plan of Merger, dated as of May 28, 2009, by and among CuraGen, Celldex and Celldex’s merger subsidiary, Cottrell Merger Sub, Inc. The Agreement and Plan of Merger was approved by CuraGen’s stockholders and the issuance of shares of Celldex common stock was approved by Celldex’s stockholders at special stockholder meetings held on September 30, 2009. Concurrent with the closing of the merger, Celldex added one position to its Board of Directors and Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen, joined the Celldex Board of Directors. “Celldex is focused on advancing our pipeline of targeted immunotherapeutics and we look forward to integrating CuraGen’s assets to augment our Precision Targeted Immunotherapy Platform,†stated Anthony Marucci, President and Chief Executive Officer of Celldex. “We’ve also signi...Click here to read the whole Article (external link)
Celldex Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results
CELLDEX THERAPEUTICS, INC. (In thousands, except share and per share amounts) Â Â Â Â Â Â CONSOLIDATED STATEMENTS Quarter Nine Months OF OPERATIONS DATA Â Ended September 30, Â Ended September 30, 2009 2008 2009 2008 (Unaudited) (Unaudited) REVENUE Product Development and ...Click here to read the whole Article (external link)
Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307
NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (NASDAQ: CLDX - News) today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer. CDX-1307, the first candidate from the Company’s Precision Targeted Immunotherapy Platform, utilizes monoclonal antibodies to deliver vaccine directly to the patient’s immune system and focuses the immune system against hCG beta (hCG-β), a cancer-associated target believed to play a role in more aggressive forms of the disease. The data, presented at the 24th Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc) in Washington, D.C., demonstrated enhanced immunological and biological responses and support the planned initiation of Phase 2 clinical trials in hCG-β expressing cancers. The Phase 1 studies investigated the safety and immunogenicity of CDX-1307 alone and in combination with adjuvants, including GM-CSF and Toll-like Receptor (TLR) agonists (poly-ICLC or Hiltonol™ and R848 or resiquimod). The studies enrolled more than 80 patients with heavily pretreated, advanced-stage breast, colon, bladder and pancreatic cancer, with an average of 4.6 prior therapies across the treatment population. All patient cohorts demonstrated a favorable safety profile with no dose limiting toxicity to date. The comb...Click here to read the whole Article (external link)
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statem
Show all filings for CELLDEX THERAPEUTICS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K/A for CELLDEX THERAPEUTICS, INC. 21-Oct-2009Completion of Acquisition or Disposition of Assets, Financial Statem Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All informatio...Click here to read the whole Article (external link)
New Star Analyst Rankings for Celldex Therapeutics, Inc
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...Click here to read the whole Article (external link)
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
Show all filings for CELLDEX THERAPEUTICS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for CELLDEX THERAPEUTICS, INC. 4-Nov-2009Results of Operations and Financial Condition, Financial Statements an Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information...Click here to read the whole Article (external link)
CELLDEX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as "may," "will," "can," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target," "potential" and other similar words and expressions of the future. There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to: † our ability to raise sufficient capital on terms acceptable to us, or at all; † our ability to successfully in...Click here to read the whole Article (external link)
CELLDEX THERAPEUTICS, INC. Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Would you like to leave a comment about Celldex Therapeutics, Inc CLDX
Find out what social network information about Celldex Therapeutics, Inc are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Celldex Therapeutics, Inc there is more great information available at Realpennies.com